Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Hydralazine
Drug ID BADD_D01081
Description Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed.[A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.[A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications.[T691] Hydralazine hydrochloride was FDA approved on 15 January 1953.[L8779]
Indications and Usage Hydralazine is indicated alone or adjunct to standard therapy to treat essential hypertension.[L8782] A combination product with isosorbide dinitrate is indicated as an adjunct therapy in the treatment of heart failure.[L8785]
Marketing Status approved
ATC Code C02DB02
DrugBank ID DB01275
KEGG ID D08044
MeSH ID D006830
PubChem ID 3637
TTD Drug ID D0K1XK
NDC Product Code Not Available
UNII 26NAK24LS8
Synonyms Hydralazine | Hydrallazin | Hydrazinophthalazine | Apressin | Nepresol | Hydralazine mono-Hydrochloride | Hydralazine mono Hydrochloride | mono-Hydrochloride, Hydralazine | Apressoline | Apresoline | Hydralazine Hydrochloride | Hydrochloride, Hydralazine
Chemical Information
Molecular Formula C8H8N4
CAS Registry Number 86-54-4
SMILES C1=CC=C2C(=C1)C=NN=C2NN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chromaturia20.02.01.0020.000150%
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Cutaneous vasculitis23.06.02.001; 24.12.04.008; 10.02.02.0030.000423%Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.11.04.006--
Duodenal ulcer haemorrhage24.07.02.020; 07.04.02.0040.000102%Not Available
Dyspepsia07.01.02.001--
Dysphonia19.19.03.002; 17.02.08.004; 22.12.03.0060.000068%
Dyspnoea02.11.05.003; 22.02.01.004--
Dyspnoea exertional02.11.05.005; 22.02.01.0050.000068%Not Available
Dysuria20.02.02.002--
Encephalopathy17.13.02.0010.000102%
Eosinophilia01.02.04.0010.000218%
Exophthalmos05.02.02.002; 06.09.04.001--Not Available
Feeling abnormal08.01.09.014--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.0250.000334%
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.0010.000205%Not Available
Glomerulonephritis20.05.01.001; 10.02.01.0060.001261%Not Available
Glomerulonephritis membranous20.05.01.0070.000170%Not Available
Glomerulonephritis proliferative20.05.01.0080.000511%Not Available
Glomerulonephritis rapidly progressive20.05.01.004; 10.04.04.0080.002659%Not Available
Granuloma skin23.03.15.0020.000068%Not Available
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.0060.000252%
Haemoglobin decreased13.01.05.003--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene